ABSTRACT
PURPOSE: Data on short courses of antibiotic therapy for Enterobacterales bacteremia in high-risk neutropenic patients are limited. The aim of the study was to describe and compare the frequency of bacteremia relapse, 30-day overall and infection-related mortality, Clostridiodes difficile infection and length of hospital stay since bacteremia among those who received antibiotic therapy for 7 or 14 days. METHODS: This is a multicenter, prospective, observational cohort study in adult high-risk neutropenic patients with hematologic malignancies or hematopoietic stem cell transplant and monomicrobial Enterobacterales bacteremia. They received appropriate empirical antibiotic therapy, had a clinical response within 7 days, and infection source control. Clinical, epidemiological and outcomes variables were compared based on 7 or 14 days of AT. RESULTS: Two hundred patients were included (100, 7-day antibiotic therapy; 100, 14-day antibiotic therapy). Escherichia coli was the pathogen most frequently isolated (47.5%), followed by Klebsiella sp. (40.5%). Among those patients that received 7-day vs. 14-day antibiotic course, a clinical source of bacteremia was found in 54% vs. 57% (p = 0.66), multidrug-resistant Enterobacterales isolates in 28% vs. 30% (p = 0.75), and 40% vs. 47% (p = 0.31) received combined empirical antibiotic therapy. Overall mortality was 3% vs. 1% (p = 0.62), in no case related to infection; bacteremia relapse was 7% vs. 2% (p = 0.17), and length of hospital stay since bacteremia had a median of 9 days (IQR: 7-15) vs. 14 days (IQR: 13-22) (p = < 0.001). CONCLUSIONS: These data suggest that seven-day antibiotic therapy might be adequate for patients with high-risk neutropenia and Enterobacterales bacteremia, who receive appropriate empirical therapy, with clinical response and infection source control.
Subject(s)
Anti-Bacterial Agents , Bacteremia , Enterobacteriaceae Infections , Neutropenia , Humans , Bacteremia/drug therapy , Bacteremia/microbiology , Bacteremia/mortality , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/administration & dosage , Male , Female , Middle Aged , Prospective Studies , Neutropenia/complications , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae Infections/mortality , Enterobacteriaceae Infections/microbiology , Adult , Aged , Enterobacteriaceae/drug effects , Treatment Outcome , Length of Stay , Hematologic Neoplasms/complications , Young AdultABSTRACT
INTRODUCTION: Despite improvements in health care, pneumonia-associated mortality remains high. The objective of this study was to analyze the factors associated with mortality in bacteremic pneumonia caused by pneumococcus. METHODS: Retrospective cohort study in adult patients with pneumonia diagnosis and isolation of pneumococcus in blood cultures, between January 2012 and May 2021, was carried out. Clinical and laboratory variables, radiological involvement, evolution and mortality during hospitalization were analyzed. The group of deceased patients was compared with that of survivors. RESULTS: 152 patients were included. Median age: 58 years; men: 58.9%; 33% presented a CURB-65 > than 2 at admission. Overall mortality: 34% (n=52). Deceased patients were more tachypneic on admission (respiratory rate 26 vs. 22; p=0.003), presented sensory alteration more frequently (58% vs. 14%; p< 0.001), PaO2/fraction of inspired oxygen ratio < 250 (58% vs. 22%; p<0.001), bilateral radiological compromise (50% vs. 32%; p=0.03), needed mechanical ventilation (50% vs 12%; p< 0.001), higher blood creatinine values (1.6 vs. 1.15; p=0.01), lower white blood cell count (10 900 vs 17 400; p=0.002), a lower glucose dosage (111 vs. 120; p=0.01), and fewer days of hospital stay (6 vs. 9; p=0.015). In logistic regression model, significant differences were maintained in the following factors associated with mortality: mechanical ventilation (OR=3.54), altered mental status (OR=5.95), chest X-ray with bilateral compromise (OR 3.20) and PAFI less than 250 (OR=3.62). CONCLUSION: In our series, the factors related to mortality, despite the presence of bacteremia, do not differ from those published in the literature and which are part of the different prognostic scores used in routine practice.
Introducción: A pesar de las mejoras en los cuidados de la salud, la mortalidad asociada a neumonía continúa siendo alta. El objetivo de este estudio fue analizar los factores asociados a mortalidad en neumonía bacteriémica por neumococo. Métodos: Estudio de cohorte retrospectiva en pacientes adultos con diagnóstico de neumonía y neumococo aislado en hemocultivos, entre enero 2012 y mayo 2021. Se analizaron: variables clínicas y de laboratorio, compromiso radiológico, evolución y mortalidad durante la internación. Se comparó el grupo de pacientes fallecidos con el de sobrevivientes. Resultados: Se incluyeron 152 pacientes. La mediana de edad fue de 58 años y el 58.9% fueron hombres. El 33% presentó un CURB-65 mayor a 2 al momento de internación. La mortalidad global fue 34% (n=52). Los pacientes fallecidos se encontraban más frecuentemente taquipneicos al ingreso (frecuencia respiratoria 26 vs. 22; p=0.003), presentaban más frecuentemente alteración del sensorio (58% vs. 14%; p< 0.001), PaO2/fracción inspirada de oxígeno (PAFI) < 250 (58% vs. 22%; p<0.001), compromiso radiológico bilateral (50% vs. 32%; p=0.03), necesidad de asistencia respiratoria mecánica (ARM) (50% vs. 12%; p< 0.001), mayor valor de creatinina en sangre (1.6 vs. 1.15; p=0.01), menor recuento de glóbulos blancos (10 900 vs. 17 400; p=0.002), menor valor de glucemia (111 vs. 120; p=0.01) y menos días de estancia hospitalaria (6 vs. 9; p=0.015). En el análisis de regresión logística multivariable se mantuvieron diferencias significativas en los siguientes factores asociados a mortalidad: ventilación mecánica (OR=3.54), confusión (OR=5.95), radiografía con compromiso bilateral (OR= 3.20) y PAFI < 250 (OR=3.62). Conclusión: Los factores relacionados con mortalidad, a pesar de la presencia de bacteriemia, no difieren de los publicados en la literatura y forman parte de los scores pronósticos de práctica habitual.
Subject(s)
Pneumonia, Pneumococcal , Humans , Male , Retrospective Studies , Middle Aged , Female , Aged , Pneumonia, Pneumococcal/mortality , Risk Factors , Adult , Streptococcus pneumoniae , Hospital Mortality , Bacteremia/mortality , Bacteremia/microbiologyABSTRACT
INTRODUCCIÓN: Las bacteriemias por Enterobacterales productores de carbapenemasa KPC (EPC-KPC) presentan una mortalidad elevada y opciones terapéuticas limitadas. OBJETIVOS: Describir y comparar la evolución de los pacientes con bacteriemia por EPC-KPC tratados con ceftazidima/avibactam (CA) frente a otros antimicrobianos (OA). PACIENTES Y MÉTODOS: Estudio prospectivo y retrospectivo de casos y controles. Se incluyeron pacientes adultos con bacteriemia por EPC-KPC, con una proporción entre casos tratados con CA y controles tratados con OA. de 1:2. Se analizaron variables clínicas, epidemiológicas y de evolución. RESULTADOS: Se incluyeron 48 pacientes (16 CA y 32 OA). Los casos se encontraban más frecuentemente neutropénicos (50 vs.16%, p = 0,012); asimismo, presentaron medianas de score de APACHE II más altas y de score de Pitt más bajas. El 65% de la cohorte total presentó un foco clínico y Klebsiellapneumoniae fue el microorganismo más frecuentemente aislado. Los casos recibieron una mayor proporción de tratamiento antimicrobiano empírico adecuado (81 vs. 53%, p = 0,05). La antibioterapia dirigida en casos y controles fue combinada en 38 y 91%, p = 0,009. Los casos presentaron menor mortalidad al día 7 y al día 30 relacionada a infección (0 vs. 22%, p = 0,04 y 0 vs. 34%, p = 0,008). Solo los controles desarrollaron shock, ingresaron a la unidad de cuidados intensivos y presentaron bacteriemia de brecha. CONCLUSIÓN: CA mostró beneficio clínico frente a OA para el tratamiento de pacientes con bacteriemia por EPC-KPC.
BACKGROUND: KPC-producing Enterobacterales bacteremia (KPCCPE) is associated with a high mortality rate and limited therapeutic options. AIM: To describe and compare the outcome of patients with KPC-CPE bacteremia treated with ceftazidime/avibactam (CA) versus other antibiotics (OA). METHODS: Prospective and retrospective cases and control study performed in adult patients with KPC-CPE bacteremia, with a 1:2 ratio between cases treated with CA. and controls treated with OA. Clinical, epidemiological, and outcome variables were analyzed. RESULTS: Forty-eight patients (16 CA and 32 OA) were included. Cases were more frequently neutropenic (50 vs. 16%, p = 0.012), presented higher median APACHE II score and lower Pitt score. Of the total cohort, 65% had a clinical source, and Klebsiella pneumoniae was the most frequently isolated microorganism. Cases received more adequate empirical antibiotic treatment (81 vs. 53%, p = 0.05). Targeted antibiotic therapy in cases and controls was combined in 38 and 91%, p = 0.009. Cases had a lower 7-day mortality and 30-day infection-related mortality (0 vs. 22%, p = 0.04 and 0 vs. 34%, p = 0.008). Only controls developed shock, were admitted to the intensive care unit, and had breakthrough bacteremia. CONCLUSION: CA. showed clinical benefit over OA in the treatment of patients with EPC-KPC bacteremia.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Ceftazidime/therapeutic use , Bacteremia/drug therapy , Enterobacteriaceae Infections/drug therapy , Azabicyclo Compounds/therapeutic use , Anti-Bacterial Agents/therapeutic use , Bacterial Proteins , beta-Lactamases , Case-Control Studies , Ceftazidime/administration & dosage , Clinical Evolution , Prospective Studies , Bacteremia/microbiology , Bacteremia/mortality , Drug Combinations , Enterobacteriaceae/isolation & purification , Enterobacteriaceae/drug effects , Enterobacteriaceae Infections/mortality , Azabicyclo Compounds/administration & dosage , beta-Lactamase Inhibitors , Anti-Bacterial Agents/administration & dosageABSTRACT
The effect of COVID-19 on the outcomes of patients with Staphylococcus aureus bacteremia is still unknown. Aim: In this study, we aimed to determine associated factors for mortality in patients with S. aureus bacteremia and to explore the impact of prior COVID-19. Design and setting: In this retrospective and single-center study, all adult patients (≥ 18 years old) with S. aureus bacteremia between March 2020 and February 2022 were included. Methods: The outcomes of our study were 14-day and 28-day hospital mortality after the first positive blood culture was obtained. Univariate and Cox regression analyses were performed. Results: A total of 140 patients with S. aureus bacteremia were included in the study. The median age was 64.5 (48.5-76) and 82 (58.5%) of the patients were male. 14-day and 28-day mortality rates were 28.6% and 37.1% respectively. Among patients with S. aureus bacteremia and previous COVID-19 history, 14-day and 28-day mortality rates were 33.9% (n = 21) and 41.9% (n = 26), respectively. Cox regression analysis revealed that Pitt bacteremia score, AST, urea, and previous antibiotic use were associated factors for 14-day mortality and 28-day mortality due to S. aureus bacteremia. Conclusions: This study justified the remarkable fatality of S. aureus bacteremia during the COVID-19 pandemic period and revealed that a high Pitt bacteremia score, increased levels of AST and urea, and previous antibiotic exposure were associated factors for mortality in patients with S. aureus bacteremia.
El efecto de COVID-19 en los resultados de pacientes con bacteriemia por Staphylococcus aureus todavía es desconocido. Objetivo: Determinar los factores asociados con la mortalidad en pacientes con bacteriemia por S. aureus y explorar el impacto del COVID-19 previo. Métodos: Estudio retrospectivo de un solo centro, que incluyó a todos los pacientes adultos (≥ 18 años) con bacteriemia por S. aureus entre marzo de 2020 y febrero de 2022. Estudiamos la mortalidad hospitalaria a los 14 y 28 días después de obtener el primer cultivo sanguíneo positivo, utilizando análisis univariados y de regresión de Cox. Resultados: Se incluyeron un total de 140 pacientes con bacteriemia por S. aureus en el estudio. La mediana de edad fue de 64,5 (48,5-76) años y 82 (58,5%) de los pacientes eran hombres. Las tasas de mortalidad a los 14 y 28 días fueron del 28,6% y 37,1%, respectivamente. Entre los pacientes con bacteriemia por S. aureus y antecedentes previos de COVID-19, las tasas de mortalidad a los 14 y 28 días fueron del 33,9% (n = 21) y 41,9% (n = 26), respectivamente. El análisis de regresión de Cox reveló que el puntaje de bacteriemia de Pitt, AST, urea y el uso previo de antibióticos fueron factores asociados con la mortalidad a los 14 y 28 días debido a la bacteriemia por S. aureus. Conclusiones: Este estudio justificó la notable letalidad de la bacteriemia por S. aureus durante el período de pandemia de COVID-19 y reveló que un puntaje de bacteriemia de Pitt elevado, niveles aumentados de AST y urea, y la exposición previa a antibióticos fueron factores asociados con la mortalidad en pacientes con bacteriemia por S. aureus.
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Staphylococcal Infections/mortality , Staphylococcus aureus/isolation & purification , Hospital Mortality , Bacteremia/microbiology , Bacteremia/mortality , COVID-19/mortality , Retrospective Studies , Risk Factors , Pandemics , SARS-CoV-2ABSTRACT
The effect of COVID-19 on the outcomes of patients with Staphylococcus aureus bacteremia is still unknown. AIM: In this study, we aimed to determine associated factors for mortality in patients with S. aureus bacteremia and to explore the impact of prior COVID-19. DESIGN AND SETTING: In this retrospective and single-center study, all adult patients (≥ 18 years old) with S. aureus bacteremia between March 2020 and February 2022 were included. METHODS: The outcomes of our study were 14-day and 28-day hospital mortality after the first positive blood culture was obtained. Univariate and Cox regression analyses were performed. RESULTS: A total of 140 patients with S. aureus bacteremia were included in the study. The median age was 64.5 (48.5-76) and 82 (58.5%) of the patients were male. 14-day and 28-day mortality rates were 28.6% and 37.1% respectively. Among patients with S. aureus bacteremia and previous COVID-19 history, 14-day and 28-day mortality rates were 33.9% (n = 21) and 41.9% (n = 26), respectively. Cox regression analysis revealed that Pitt bacteremia score, AST, urea, and previous antibiotic use were associated factors for 14-day mortality and 28-day mortality due to S. aureus bacteremia. CONCLUSIONS: This study justified the remarkable fatality of S. aureus bacteremia during the COVID-19 pandemic period and revealed that a high Pitt bacteremia score, increased levels of AST and urea, and previous antibiotic exposure were associated factors for mortality in patients with S. aureus bacteremia.
Subject(s)
Bacteremia , COVID-19 , Hospital Mortality , Staphylococcal Infections , Staphylococcus aureus , Humans , COVID-19/mortality , Male , Retrospective Studies , Female , Middle Aged , Bacteremia/mortality , Bacteremia/microbiology , Aged , Staphylococcal Infections/mortality , Staphylococcus aureus/isolation & purification , Risk Factors , SARS-CoV-2 , PandemicsABSTRACT
Introducción: En los niños, la bacteriemia por Stenotrophomonas maltophilia es considerada una complicación severa y asociada a una elevada mortalidad. Con el objetivo de conocer la mortalidad asociada a esa condición, se realizó una revisión sistemática de la literatura. Material y métodos: Se aplicó una estrategia de búsqueda bibliográfica con las palabras clave: bacteriemia por Stenotrophomonas maltophilia, niños y adolescentes como únicos filtros. Se informan la mediana y los valores intercuartílicos de la frecuencia de la mortalidad reportada por los estudios incluidos. Resultados: Se identificaron 165 estudios potencialmente útiles. De ellos, se seleccionaron finalmente, 9 estudios para ser incluidos. La incidencia de mortalidad a consecuencia de una bacteriemia por S.maltophilia fue del 25%; Q25: 11Q75: 36; rango: 6,06 a 40,6. Consideraciones finales: La bacteriemia por Sm tuvo un alto porcentaje de mortalidad en especial en pacientes con patología subyacente y uso de procedimientos invasivos y el uso inadecuado de antibióticos empíricos (AU)
Introduction: In children, Stenotrophomonas maltophilia-related bacteremia is considered a severe complication associated with high mortality. With the aim to determine the mortality associated with this condition, a systematic review of the literature was conducted. Material and methods: A literature search strategy was applied using the keywords: bacteremia due to Stenotrophomonas maltophilia, children, and adolescents as the only filters. The median and interquartile ranges of the mortality rates described in the studies included are reported. Results: A total of 165 potentially useful studies were identified, of which nine were finally selected to be included in the analysis. The incidence of S.maltophilia bacteremia-related mortality was 25%; Q25: 11Q75: 36; range: 6.06 to 40.6. Final considerations: S.maltophilia-related bacteremia was associated with a high mortality rate especially in patients with an underlying disease, when invasive procedures were performed, and when emperical antibiotics were inadequately used (AU)
Subject(s)
Humans , Infant , Child, Preschool , Child , Adolescent , Gram-Negative Bacterial Infections/mortality , Bacteremia/mortality , Stenotrophomonas maltophilia/isolation & purification , Immunocompromised Host , Anti-Bacterial Agents/therapeutic useABSTRACT
INTRODUCCIÓN: En los niños, la bacteriemia debida a Burkholderia cepacia, es considerada una complicación grave y conducente a una elevada mortalidad. Con el objetivo de conocer la mortalidad asociada a esa condición, se realizó una revisión sistemática de la literatura médica. MATERIAL Y MÉTODOS: Se aplicó una estrategia de búsqueda bibliográfica con las palabras claves: "bacteriemia por B. cepacia", "humanos", "niños" y "adolescentes", como únicos filtros. Se informan la mediana y los valores intercuartílicos de la frecuencia de la mortalidad reportada por los estudios incluidos. RESULTADOS: Se identificaron 92 estudios potencialmente útiles. De ellos, se descartaron 81, incluyéndose finalmente, 11 estudios. Se trató de descripciones retrospectivas de casos, salvo uno de ellos, que respondió a un diseño analítico caso-control. La mediana de la mortalidad reportada por esta revisión, fue 0 (Q25 = 0 y Q75 = 28,57%). INTERPRETACIÓN: Si bien la evidencia disponible es escasa y de baja calidad, sugiere que el curso clínico de esta afección no siempre resulta en una elevada mortalidad.
BACKGROUND: Bacteremia due to Burkolderia cepacia in children is considered a severe complication and associated with high mortality incidence. In order to know the level of mortality associated with it, this systematic review of the literature was carried out. METHODS: A search strategy was carried out with the keywords: "bacteremia by B cepacia and human" and "children" and "adolescents" as filters. Global frequency of mortality reported by the included studies was calculated and informed as median (Q2) and its interquartile values (Q1 and Q3). RESULTS: The search identified 92 potentially useful studies. Of these, 81 were discarded, and then remained 11 studies to be included. One out of 11 studies is an analytic case-control design. Rest are retrospective case series. Related mortality median was 0 (Q25 = 0 and Q75 = 28,57%). CONCLUSION: Although the available evidence is scarce and of low quality, it suggests that clinical course of this condition does not always lead to high mortality rates.
Subject(s)
Humans , Child , Bacteremia/mortality , Burkholderia Infections/mortality , Burkholderia cepaciaABSTRACT
BACKGROUND: Previous studies have found that healthcare-associated bacteremia (HAB) by Aeromonas species is associated with mortality. However, there is limited data on this outcome in patients with hematologic malignancies. This study aimed to identify the clinical features of patients with malignant hematologic diseases diagnosed with Aeromonas sobria bacteremia and to evaluate whether the type of bacteremia, community-acquired bacteremia (CAB) or HAB, is associated with mortality. METHODS: We retrospectively reviewed the clinical records of pediatric and adult patients between January 2000 and December 2017. Clinical characteristics were compared between CAB and HAB. Additionally, we stratified based on age group. Survival outcomes were assessed with Kaplan-Meier curves and a multivariate Cox regression analysis. RESULTS: A total of 37 patients (median age 24 years) were identified; 23 (62%) had HAB and 14 (38%) had CAB. Overall, the most common presenting symptom was abdominal pain (41%). Acute lymphoblastic leukemia (n = 12/15, 80%) and acute myeloid leukemia (n = 8/22, 36%) were the primary hematologic malignancies in pediatric and adult patients, respectively. CAB patients had worse overall survival (OS) rates at 30 days in all (43% versus HAB 91%, p = 0.006) and adult patients (30% versus HAB 92%, p = 0.002). Cox regression analysis found that quick Sequential Organ Failure Assessment and CAB were statistically significant factors associated with mortality. Low antimicrobial-resistant was noted, except for ciprofloxacin (n = 5/37, 14%). CONCLUSION: Our study found a worse OS among patients with hematologic malignancies and CAB by Aeromonas sobria. Our results suggest that patients with CAB present with a worse disease severity. These findings should aid clinicians to determine the survival prognosis in this population.
Subject(s)
Aeromonas/isolation & purification , Bacteremia/pathology , Hematologic Neoplasms/pathology , Adolescent , Adult , Aeromonas/drug effects , Aged , Bacteremia/complications , Bacteremia/microbiology , Bacteremia/mortality , Child , Child, Preschool , Ciprofloxacin/pharmacology , Cross Infection/complications , Cross Infection/microbiology , Cross Infection/mortality , Cross Infection/pathology , Drug Resistance, Bacterial/drug effects , Female , Hematologic Neoplasms/complications , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multiple Organ Failure , Peru , Proportional Hazards Models , Retrospective Studies , Young AdultABSTRACT
INTRODUCTION: Bacteremia is a major cause of morbidity and mortality in hospitalized patients. Predictors of mortality are critical for the management and survival of hospitalized patients. The objective of this study was to determine the factors related to blood culture positivity and the risk factors for mortality in patients whose blood cultures were collected. METHODS: A prospective 2-cohort study (derivation with 784 patients and validation with 380 patients) based on the Pitt bacteremia score for all patients undergoing blood culture collection. The score was obtained from multivariate analysis. The Kaplan-Meier survival curve of the cohort derivation and the cohort validation groups was calculated, and the difference was assessed using a log-rank test. Mortality-related factors were older age, extended hospitalization, > 10% of immature cells in the leukogram, lower mean blood pressure, elevated heart rate, elevated WBC count, and elevated respiratory rate. These continuous variables were dichotomized according to their significance level, and a cut-off limit was created. RESULTS: The area under the ROC curve (AUC) was 0.789. The score was validated in a group of 380 patients who were prospectively evaluated. CONCLUSION: Prolonged hospitalization, body temperature, and elevated heart rate were related to positive blood cultures. The Pitt score can be used to assess the risk of death; however it can be individualized according to the epidemiology of each hospital.
Subject(s)
Bacteremia , Blood Culture , Fungemia , Microbiological Techniques , Adult , Aged , Bacteremia/diagnosis , Bacteremia/epidemiology , Bacteremia/mortality , Brazil/epidemiology , Cohort Studies , Fungemia/diagnosis , Fungemia/epidemiology , Fungemia/mortality , Humans , Microbiological Techniques/standards , Middle Aged , Models, Statistical , Predictive Value of Tests , Prospective Studies , ROC Curve , Reproducibility of Results , Retrospective Studies , Risk FactorsABSTRACT
Introduction: The bacteremia caused by Staphylococcus aureus acquired in the community (SA-AC) is a frequent pathology in pediatrics and it is considered a public health problem generating high rates of morbidity, mortality, and bacterial resistance. Objectives: To analyze the factors related to death and admission to intensive care units of patients under 18 years of age with AC-SA bacteremia admitted to the Hospital Infantil Los Ángeles, Pasto, Colombia, from 2014 to 2017. Material and methods: We conducted a descriptive, transversal, cross-sectional observational study. We analyzed 86 patients with bacteremia due to AC-SA that met the inclusion criteria for the study using a multivariate logistic regression model. Results: Of the 86 cases, 25.6% died and 40.7% entered the intensive care unit. The resistance to methicillin was 52.3%. The main foci of infection were the soft tissues and the osteoarticular and respiratory systems; 32.6% of patients came from the Pacific area of Nariño. The predominant ethnic groups were the mestizo and the indigenous. Indigenous patients had higher mortality compared to the mestizo and Afro-Colombian ethnic groups. The multivariate analysis showed significance in terms of death for endocarditis (adjusted OR=20; CI: 1.5-254; p=0.02) while no statistical significance was registered for the admission to the intensive care unit. Conclusions: The AC-SA led to high mortality and admission to the intensive care unit; 52.3% of strains were resistant and resistance to methicillin showed higher mortality, although the mortality with sensitive strains was considerable. Endocarditis showed fairly high mortality. The empirical therapy should be adjusted when bacteremia due to AC-SA is suspected.
Introducción. La bacteriemia por Staphylococcus aureus adquirida en la comunidad (SAAC) es una condición frecuente en pediatría que, además, constituye un problema de salud pública por las altas tasas de morbimortalidad y de resistencia bacteriana. Objetivos. Analizar los factores relacionados con la muerte y el ingreso a cuidados intensivos de pacientes menores de 18 años con bacteriemia por SA-AC que ingresaron al Hospital Infantil Los Ángeles de Pasto, Colombia, entre el 2014 y el 2017. Materiales y métodos. Se hizo un estudio observacional descriptivo y transversal. Se analizaron 86 pacientes con bacteriemia por SA-AC que cumplían los criterios de inclusión en el estudio utilizando un modelo multivariado de regresión logística. Resultados. El 25,6 % de los 86 pacientes falleció y el 40,7 % ingresó a la unidad de cuidados intensivos. La resistencia a la meticilina fue de 52,3 %. Los focos principales de infección fueron los tejidos blandos, el sistema osteoarticular y el respiratorio. El 32,6 % de los pacientes provenía de la zona del Pacífico de Nariño. Las etnias predominantes fueron la mestiza y la indígena. Entre los indígenas hubo mayor mortalidad que entre mestizos y afrocolombianos. En el análisis multivariado de la variable de muerte, se registró significación de la endocarditis (odds ratio, OR ajustado=20; IC95%1,5-254; p=0,02); no se registró significación estadística en cuanto al ingreso en la unidad de cuidados intensivos. Conclusiones. La bacteriemia por SA-AC determinó altas tasas de mortalidad e ingreso a la unidad de cuidados intensivos. Las cepas resistentes representaron el 52,3 %, y la resistencia a la meticilina desembocó en una mayor mortalidad, aunque la mortalidad con cepas sensibles también fue considerable. La endocarditis fue responsable de una mortalidad bastante elevada. Se debe ajustar el tratamiento empírico cuando se sospeche bacteriemia por SA-AC.
Subject(s)
Bacteremia/mortality , Hospitalization/statistics & numerical data , Intensive Care Units, Pediatric/statistics & numerical data , Staphylococcal Infections/mortality , Staphylococcus aureus , Adolescent , Child , Child, Preschool , Colombia/epidemiology , Community-Acquired Infections/mortality , Cross-Sectional Studies , Female , Humans , Infant , Male , Time FactorsABSTRACT
To evaluate the prognostic factors in adult cancer patients with pneumococcal bacteremia, describe episode features and the phenotypic characteristics of the isolated strains. We evaluated the episodes in patients admitted to a cancer hospital between 2009 and 2015. The outcomes were defined as 48 h mortality and mortality within 10 days after the episode. The variables evaluated were: age, sex, ethnicity, ECOG, Karnofsky score, SOFA, cancer type, metastasis, chemotherapy, radiotherapy, neutropenia, previous antibiotic therapy, community or healthcare-acquired infection, comorbidities, smoking, pneumococcal vaccination, infection site, presence of fever, polymicrobial infection, antimicrobial susceptibility, serotype and treatment. 165 episodes were detected in 161 patients. The mean age was 61.3 years; solid tumors were the most prevalent (75%). 48 h and 10-day mortality were 21% (34/161) and 43% (70/161) respectively. The 48 h mortality- associated risk factors were SOFA and polymicrobial bacteremia; 10-day mortality-associated risk factors were fever, neutropenia, ECOG 3/4, SOFA and fluoroquinolones as a protective factor. Pneumococcal bacteremia presented high mortality in cancer patients, with prognosis related to intrinsic host factors and infection episodes features. Fluoroquinolone treatment, a protective factor in 10-day mortality, has potential use for IPDs and severe community-acquired pneumonia in cancer patients.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacteremia/mortality , Fluoroquinolones/therapeutic use , Neoplasms/complications , Pneumococcal Infections/mortality , Adult , Aged , Aged, 80 and over , Bacteremia/drug therapy , Bacteremia/microbiology , Brazil/epidemiology , Female , Humans , Male , Middle Aged , Pneumococcal Infections/drug therapy , Pneumococcal Infections/microbiology , Retrospective Studies , Streptococcus pneumoniaeABSTRACT
Introduction. Bloodstream infection is one of the most frequent and challenging hospital-acquired infections and it is associated with high morbidity, mortality and additional use of healthcare resources.Hypothesis/Gap Statement: Bloodstream infections have consequences for the patient, such as the evolution to mortality and inappropriate empirical antibiotic prescription, especially when caused by multidrug-resistant Gram-negative bacilli.Objective. To assess the impact of bloodstream infection and the status of multidrug resistance (MDR) in the evolution of patients who received inappropriate initial antibiotic therapy.Methods. A retrospective surveillance was conducted on nosocomial bloodstream infections caused by Gram-negative bacilli (GNB) from January 2012 to December 2018 in an adult intensive care unit of a Brazilian tertiary teaching hospital.Results. We identified 270 patients with GNB nosocomial bacteremia. Non-survivors were older (with an average age of 58.8 years vs 46.9 years, P=<0.0001), presented more severe illnesses, were immunosuppressed (73.7 vs 37.6%, P=<0.0001), were more likely to have septic shock (55.8 vs 22.4%, P=<0.0001) and had an increased usage of mechanical ventilators (98.6 vs 89.6%, P=0.0013) than survivors. In a logistic regression model, inappropriate empirical antibiotic therapy was not an independent predictor of mortality, different from mechanical ventilator (P=<0.0001; OR=28.0; 95% CI=6.3-123.6), septic shock (P=0.0051; OR=2.5; 95% CI=1.3-4.9) and immunosuppression (P=0.0066; OR=2.6; 95% CI=1.3-5.2). In contrast, in a separate model, MDR was strongly associated with the prescription of inappropriate initial antibiotic therapy (P=0.0030; OR=5.3; 95% CI=1.7-16.1). The main isolated pathogens were Acinetobacter baumannii (23.6â%) and Klebsiella pneumoniae (18.7â%). The frequency of MDR organisms was high (63.7â%), especially among non-fermenting bacilli (60.9â%), highlighting A. baumannii (81.6â%) and Pseudomonas aeruginosa (41.8â%).Conclusion. Illness severity (septic shock and immunosuppression) and mechanical ventilation were identified as predictors of mortality. Additionally, MDR was a major determinant of inappropriate antibiotic empirical therapy, but not associated with mortality, and both characteristics were not statistically associated with death.
Subject(s)
Bacteremia/microbiology , Cross Infection/microbiology , Gram-Negative Bacteria/isolation & purification , Gram-Negative Bacterial Infections/microbiology , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/epidemiology , Bacteremia/mortality , Brazil , Cross Infection/drug therapy , Cross Infection/epidemiology , Cross Infection/mortality , Drug Resistance, Multiple, Bacterial , Female , Gram-Negative Bacteria/classification , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/genetics , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/epidemiology , Gram-Negative Bacterial Infections/mortality , Hospitals, Teaching/statistics & numerical data , Humans , Male , Middle Aged , Retrospective Studies , Tertiary Care Centers/statistics & numerical data , Young AdultABSTRACT
BACKGROUND: Despite high mortality rates, physicians can alter the course of the Staphylococcus aureus bacteraemia (SAB) by following recommended standards of care. We aim to assess the adherence of these guidelines and their impact on mortality. METHODS: Substudy from a prospective cohort of hospitalized patients with SAB from three hospitals from Peru. Hazard ratios were calculated using Cox proportional regression to evaluate the association between 30-day mortality and the performance of standards of care: removal of central venous catheters (CVC), follow-up blood cultures, echocardiography, correct duration, and appropriate definitive antibiotic therapy. RESULTS: 150 cases of SAB were evaluated; 61.33% were MRSA. 30-day attributable mortality was 22.39%. CVC removal was done in 42.86% of patients. Follow-up blood cultures and echocardiograms were performed in 8% and 29.33% of cases, respectively. 81.33% of cases had appropriate empirical treatment, however, only 22.41% of MSSA cases were given appropriate definitive treatment, compared to 93.47% of MRSA. The adjusted regression for all-cause mortality found a substantial decrease in hazards when removing CVC (aHR 0.28, 95% CI: 0.10 - 0.74) and instituting appropriate definitive treatment (aHR 0.27, 95% CI: 0.08 - 0.86), while adjusting for standards of care, qPitt bacteraemia score, comorbidities, and methicillin susceptibility; similar results were found in the attributable mortality model (aHR 0.24, 95% CI: 0.08 - 0.70 and aHR 0.21, 95% CI: 0.06 - 0.71, respectively). CONCLUSIONS: Deficient adherence to standards of care was observed, especially definitive treatment for MSSA. CVC removal and the use of appropriate definitive antibiotic therapy reduced the hazard mortality of SAB.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/mortality , Staphylococcal Infections/drug therapy , Staphylococcal Infections/mortality , Adult , Aged , Bacteremia/epidemiology , Bacteremia/microbiology , Cohort Studies , Comorbidity , Female , Guideline Adherence , Humans , Male , Middle Aged , Peru/epidemiology , Prospective Studies , Standard of Care , Staphylococcal Infections/epidemiology , Staphylococcal Infections/microbiology , Staphylococcus aureus/drug effects , Staphylococcus aureus/genetics , Staphylococcus aureus/physiologyABSTRACT
INTRODUCTION: The present study aimed to determine the incidence of health care-associated infections (HCAIs) and identify the main resistant microorganisms in intensive care unit (ICU) patients in a Brazilian university hospital. METHODS: A retrospective cohort study was conducted in a Brazilian teaching hospital between 2012 and 2014. RESULTS: Overall, 81.2% of the infections were acquired in the ICU. The most common resistant pathogenic phenotypes in all-site and bloodstream infections were oxacillin-resistant coagulase-negative staphylococci and carbapenem-resistant Acinetobacter spp. (89.9% and 87.4%; 80.6% and 70.0%), respectively. CONCLUSIONS: There is an urgent need to focus on HCAIs in ICUs in Brazil.
Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteremia/microbiology , Drug Resistance, Bacterial , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Adult , Bacteremia/mortality , Female , Gram-Negative Bacteria/classification , Gram-Negative Bacteria/isolation & purification , Gram-Positive Bacteria/classification , Gram-Positive Bacteria/isolation & purification , Hospital Mortality , Humans , Incidence , Intensive Care Units , Male , Microbial Sensitivity Tests , Middle Aged , Retrospective Studies , Time FactorsABSTRACT
Stenotrophomonas maltophilia is a multidrug-resistant, Gramnegative, and biofilm-forming pathogen. Information is limited concerning S. maltophilia bacteremia in children. Clinical data and microbiological test results collected in a tertiary children's hospital over a ten-year period were reviewed. Children 0-18 years old who had positive clinical specimen, blood and/or catheter cultures were included. We identified 20 S. maltophilia isolates from 12 pediatric patients with confirmed infections. The median age was 28 months (range: 3.1-187.3). The rate of previous use of antimicrobial therapy was 83 %. The median antibiotic number was 3 (range: 0-7) within 30 days prior to onset of S. maltophilia bacteremia. Catheter related infection was the main infectious source (66.6 %). The mortality rate was 33.3 %. The death of two non-survivors was associated with pneumonia. S. maltophilia should be considered a breakthrough agent for bacteremia in children with underlying disease exposed to broad-spectrum antibiotics during long-term hospitalization.
Stenotrophomonas maltophilia es un microorganismo gramnegativo, multirresistente. La información sobre la bacteriemia por S. maltophilia en niños es limitada. Se revisaron los datos de 10 años de un hospital de niños de alta complejidad. Se incluyó a niños de 0 a 18 años con hemocultivos o cultivos del catéter positivos. Se identificaron 20 cepas de S. maltophilia en 12 niños con infección confirmada, cuya mediana de edad fue 28 meses (intervalo: 3,1-187,3). El índice de antibioticoterapia previa fue 83 %, con una mediana de tres antibióticos (intervalo: 07) en los 30 días previos a la bacteriemia por S. maltophilia. La infección relacionada con el catéter fue la principal fuente de infección (8/12). La mortalidad fue de 4/12; y en dos casos, estuvo asociada con neumonía. S. maltophilia puede considerarse un agente muy invasivo productor de bacteriemia en niños con enfermedad preexistente expuestos a antibióticos durante una hospitalización prolongada.
Subject(s)
Bacteremia/diagnosis , Bacteremia/microbiology , Gram-Negative Bacterial Infections/diagnosis , Gram-Negative Bacterial Infections/microbiology , Stenotrophomonas maltophilia/immunology , Adolescent , Anti-Bacterial Agents/adverse effects , Bacteremia/etiology , Bacteremia/mortality , Catheter-Related Infections/diagnosis , Catheter-Related Infections/etiology , Catheter-Related Infections/microbiology , Catheter-Related Infections/mortality , Child , Child, Preschool , Cross Infection/diagnosis , Cross Infection/etiology , Cross Infection/microbiology , Cross Infection/mortality , Female , Gram-Negative Bacterial Infections/etiology , Gram-Negative Bacterial Infections/mortality , Hospitalization , Humans , Infant , Infant, Newborn , Male , Retrospective Studies , Risk FactorsABSTRACT
Intensive care unit-acquired bloodstream infections (ICU-BSI) are frequent and are associated with high morbidity and mortality rates. We conducted this study to describe the epidemiology and the prognosis of ICU-BSI in our ICU and to search for factors associated with mortality at 28 days. For this, we retrospectively studied ICU-BSI in the ICU of the Cayenne General Hospital, from January 2013 to June 2019. Intensive care unit-acquired bloodstream infections were diagnosed in 9.5% of admissions (10.3 ICU-BSI/1,000 days). The median delay to the first ICU-BSI was 9 days. The ICU-BSI was primitive in 44% of cases and secondary to ventilator-acquired pneumonia in 25% of cases. The main isolated microorganisms were Enterobacteriaceae in 67.7% of patients. They were extended-spectrum beta-lactamase (ESBL) producers in 27.6% of cases. Initial antibiotic therapy was appropriate in 65.1% of cases. Factors independently associated with ESBL-producing Enterobacteriaceae (ESBL-PE) as the causative microorganism of ICU-BSI were ESBL-PE carriage before ICU-BSI (odds ratio [OR]: 7.273; 95% CI: 2.876-18.392; P < 0.000) and prior exposure to fluoroquinolones (OR: 4.327; 95% CI: 1.120-16.728; P = 0.034). The sensitivity of ESBL-PE carriage to predict ESBL-PE as the causative microorganism of ICU-BSI was 64.9% and specificity was 81.2%. Mortality at 28 days was 20.6% in the general population. Factors independently associated with mortality at day 28 from the occurrence of ICU-BSI were traumatic category of admission (OR: 0.346; 95% CI: 0.134-0.894; P = 0.028) and septic shock on the day of ICU-BSI (OR: 3.317; 95% CI: 1.561-7.050; P = 0.002). Mortality rate was independent of the causative organism.
Subject(s)
Bacteremia/epidemiology , Catheter-Related Infections/epidemiology , Cross Infection/epidemiology , Drug Resistance, Multiple, Bacterial , Adult , Anti-Bacterial Agents/therapeutic use , Bacteremia/microbiology , Bacteremia/mortality , Bacteremia/therapy , Candidemia/epidemiology , Candidemia/mortality , Candidemia/therapy , Carrier State/epidemiology , Catheter-Related Infections/microbiology , Catheter-Related Infections/mortality , Catheter-Related Infections/therapy , Catheterization, Central Venous/statistics & numerical data , Catheterization, Peripheral/statistics & numerical data , Coma/epidemiology , Comorbidity , Cross Infection/microbiology , Cross Infection/mortality , Cross Infection/therapy , Enterobacteriaceae Infections/epidemiology , Female , French Guiana/epidemiology , Humans , Intensive Care Units , Length of Stay/statistics & numerical data , Male , Middle Aged , Organ Dysfunction Scores , Pneumonia, Ventilator-Associated/epidemiology , Pneumonia, Ventilator-Associated/therapy , Prognosis , Renal Replacement Therapy/statistics & numerical data , Respiration, Artificial/statistics & numerical data , Respiratory Insufficiency/epidemiology , Retrospective Studies , Shock/epidemiology , Staphylococcal Infections/epidemiology , Staphylococcal Infections/microbiology , Staphylococcal Infections/mortality , Staphylococcal Infections/therapy , Wounds and Injuries/epidemiologyABSTRACT
Abstract INTRODUCTION: The present study aimed to determine the incidence of health care-associated infections (HCAIs) and identify the main resistant microorganisms in intensive care unit (ICU) patients in a Brazilian university hospital. METHODS: A retrospective cohort study was conducted in a Brazilian teaching hospital between 2012 and 2014. RESULTS: Overall, 81.2% of the infections were acquired in the ICU. The most common resistant pathogenic phenotypes in all-site and bloodstream infections were oxacillin-resistant coagulase-negative staphylococci and carbapenem-resistant Acinetobacter spp. (89.9% and 87.4%; 80.6% and 70.0%), respectively. CONCLUSIONS: There is an urgent need to focus on HCAIs in ICUs in Brazil.
Subject(s)
Humans , Male , Female , Adult , Bacteremia/microbiology , Drug Resistance, Bacterial , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Anti-Bacterial Agents/pharmacology , Time Factors , Microbial Sensitivity Tests , Incidence , Retrospective Studies , Hospital Mortality , Bacteremia/mortality , Gram-Negative Bacteria/isolation & purification , Gram-Negative Bacteria/classification , Gram-Positive Bacteria/isolation & purification , Gram-Positive Bacteria/classification , Intensive Care Units , Middle AgedABSTRACT
In this article, we report a case series of patients with infections caused by Enterobacteriales coresistant to carbapenems and polymyxins who were treated with ceftazidime/avibactam (CAZ-AVI) salvage therapy on a compassionate-use protocol. We enrolled 29 adult patients in 3 centers that had an infection due to a resistant microorganism and for whom the treatments available were considered ineffective, treated them with CAZ-AVI, and assessed clinical and microbiological cure at the end of treatment and all-cause mortality at 14 days and 30 days. The antimicrobial susceptibility profile was determined using broth microdilution, and total genomic DNA was sequenced. Twelve (41.4%) patients had bacteremia, and 48.3% (14/29) of the infections were treated with combination therapy. All strains were producers of KPC-2 and were susceptible to CAZ-AVI (MIC90, 1 µg/ml). Clinical success was high (24/29 [82.7%; 95% confidence interval, 64.2 to 94.2%]), even for the bacteremic cases (75%). The 14-day and 30-day mortality rates were 9/29 (31%) and 15/29 (51.7%), respectively. The 14-day mortality rate for pneumonia was the same as that for bloodstream infections (33.3%) and although not significant, we found that patients with renal impairment that received adjusted doses of CAZ-AVI had high mortality (4/9 [44%]; P = 0.22). We concluded that CAZ-AVI is an option for the treatment of severe infections due to difficult-to-treat drug-resistant Enterobacteriales.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Azabicyclo Compounds/therapeutic use , Bacteremia/drug therapy , Ceftazidime/therapeutic use , Drug Resistance, Multiple, Bacterial/drug effects , Enterobacteriaceae Infections/drug therapy , Pneumonia, Bacterial/drug therapy , Salvage Therapy/methods , Adult , Bacteremia/microbiology , Bacteremia/mortality , Bacteremia/pathology , Carbapenems/therapeutic use , Drug Combinations , Drug Resistance, Multiple, Bacterial/genetics , Enterobacteriaceae/drug effects , Enterobacteriaceae/enzymology , Enterobacteriaceae/growth & development , Enterobacteriaceae/pathogenicity , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae Infections/mortality , Enterobacteriaceae Infections/pathology , Female , Gene Expression , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/mortality , Pneumonia, Bacterial/pathology , Polymyxins/therapeutic use , Prospective Studies , Survival Analysis , beta-Lactamases/genetics , beta-Lactamases/metabolismABSTRACT
BACKGROUND: This study aimed to evaluate the oral switch (OS) stewardship intervention in the intensive care unit (ICU). METHODS: This was a retrospective study with a convenience sample in two Brazilian ICUs from different hospitals in patients with sepsis receiving antibiotic therapy. The stewardship intervention included OS in patients diagnosed with sepsis when clinical stability was achieved. The primary outcome was overall mortality. Other variables evaluated were as follows: cost of antimicrobial treatment, daily costs of intensive care, acute kidney injury, and length of stay. RESULTS: There was no difference in mortality between the OS and non-OS groups (p = 0.06). Length of stay in the ICU (p = 0.029) was shorter and acute kidney injury incidence (p = 0.032) and costs of antimicrobial therapy (p < 0.001) were lower in the OS group. CONCLUSION: OS stewardship programs in the ICU may be considered a safe strategy. Switch therapy reduced the cost and shortened the length of stay in ICUs.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Bacteremia/drug therapy , Bacteremia/mortality , Acute Kidney Injury/chemically induced , Administration, Intravenous , Administration, Oral , Aged , Anti-Bacterial Agents/economics , Anti-Bacterial Agents/therapeutic use , Bacteremia/economics , Brazil , Costs and Cost Analysis , Cross-Sectional Studies , Female , Humans , Intensive Care Units/statistics & numerical data , Length of Stay , Male , Middle Aged , Retrospective Studies , Treatment OutcomeABSTRACT
Extraintestinal pathogenic Escherichia coli (ExPEC) isolates are responsible for many bloodstream infections. The aim of this study was to characterize E. coli isolated from the bloodstreams of patients (n = 48) at the University Hospital in Brazil. Epidemiological data were obtained through the analysis of medical records and laboratory tests. By PCR analysis, we investigated the presence of virulence factors (VFs), pathogenicity islands (PAIs), extended-spectrum ß-lactamase (ESBL), phylogenetic classifications (A, B1, B2, C, D, E, and F) and molecular genotype by enterobacterial repetitive intergenic consensus-polymerase chain reaction (ERIC-PCR). The mortality analysis showed that 33.3% of the deaths were associated with bacteraemia due to E. coli infections; in addition, an age between 60 and 75 years (p < 0.001; OR = 6.3[2.1-18.9]) and bacteraemia with an abdominal origin (p = 0.02; OR = 5[1.2-20.5]) were risk factors for the severity of the infection. Additionally, the presence of the afa gene was associated with mortality due to E. coli bacteraemia (p = 0.027; OR = 11.4[1.5-85.7]). Immunosuppression (27.1%), intestinal diseases (25.0%) and diabetes (18.8%), were prevalent among patients, and most of the bacteraemia cases were secondary to urinary tract infections (50.0%). The serum resistance gene traT was present in 77.1% of isolates, group capsular 2 (kpsMT II) was present in 45.8% and the K5 capsule was present in 20.8% of isolates. The isolates also showed a high prevalence for the siderophore yersiniabactina (fyuA) (70.8%) and PAI IV536 (77.1%). Phylogenetic analysis showed that group B2 (45.8%) was the most prevalent, and was the phylogroup that had a higher prevalence of VFs and PAIs. However, in this study, a considerable number of isolated bacteria were classified as group B1 (18.8%) and as group E (14.6%). Eight (16.7%) isolates were resistant to third and fourth generation cephalosporin and group CTX-M-1 (CTX-M-15) was the most prevalent ESBL type. The molecular genotyping showed two clonal lineages and several isolates that were not related to each other. This study provides additional information on the epidemiological and molecular characteristics of E. coli bloodstream infections in Brazil.